Efficacy of Mobile Phone-Delivered Smoking Cessation Interventions for Socioeconomically Disadvantaged Individuals: A Randomized Clinical Trial.
Journal
JAMA internal medicine
ISSN: 2168-6114
Titre abrégé: JAMA Intern Med
Pays: United States
ID NLM: 101589534
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
pubmed:
18
12
2018
medline:
23
2
2020
entrez:
18
12
2018
Statut:
ppublish
Résumé
Limited evidence supports mobile phone-delivered cessation interventions for socioeconomically disadvantaged individuals. To assess the efficacy of mobile phone-delivered cessation interventions targeted to smokers at neighborhood sites serving racial/ethnic minority and socioeconomically disadvantaged individuals. This group-randomized clinical trial with neighborhood site serving as the sampling unit compared smoking cessation interventions that included (1) nicotine replacement therapy (NRT), (2) NRT plus text messaging, and (3) NRT plus text messaging plus proactive counseling via mobile phone. Recruitment took place at churches, public housing complexes, and community centers located throughout the Houston, Texas, area. A total of 624 current cigarette smokers 18 years or older were enrolled at neighborhood sites from August 13, 2011, through December 12, 2014. Final follow-up was completed on June 12, 2015, and data were analyzed from August 17, 2017, through May 10, 2018, based on intention to treat. Nicotine replacement therapy consisted of transdermal nicotine patches; NRT plus text messages, transdermal nicotine patches and individually tailored mobile phone text messages; and NRT plus text plus call, transdermal patches, individually tailored mobile phone text messages, and proactive counseling via mobile phone. The primary outcome was smoking abstinence at 6 months, defined as (1) biochemically verified smoking abstinence (calculated among a subgroup of 377 participants) as determined by saliva cotinine level; and (2) self-reported 30-day abstinence (calculated among all 624 participants). The study sample included 624 current cigarette smokers (50.6% female; mean [SD] age, 45.8 [12.8] years). Among the 377 participants eligible for biochemical verification, 127 self-reported 30-day abstinence and were asked to provide saliva samples. Of these, 98 samples were returned (participants who did not return samples were coded as smoking). Biochemically verified abstinence rates were 12.0% for NRT, 12.0% for NRT plus text, and 25.5% for NRT plus text plus call. Participants in the NRT plus text plus call group were 2.11 (95% CI, 1.00-4.48) times more likely to be biochemically verified as abstinent compared with the NRT group. No differences in biochemically verified abstinence between the NRT plus text group and the NRT group were observed. Similar associations were observed with the self-report cessation outcomes. Findings indicate that assignment to an intervention consisting of text messaging alone may not increase cessation rates for socioeconomically disadvantaged smokers. However, text messaging plus proactive counseling may be an efficacious option. ClinicalTrials.gov identifier: NCT00948129.
Identifiants
pubmed: 30556832
pii: 2718340
doi: 10.1001/jamainternmed.2018.5713
pmc: PMC6439644
doi:
Substances chimiques
Nicotine
6M3C89ZY6R
Banques de données
ClinicalTrials.gov
['NCT00948129']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-174Subventions
Organisme : NCI NIH HHS
ID : P30 CA225520
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104938
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Addiction. 2017 Dec;112(12):2227-2236
pubmed: 28834608
Prenat Diagn. 2013 Mar;33(3):245-50
pubmed: 23354850
BMC Public Health. 2012 Aug 25;12:696
pubmed: 22920991
Cancer Causes Control. 2013 Jun;24(6):1223-30
pubmed: 23553611
MMWR Morb Mortal Wkly Rep. 2016 Nov 11;65(44):1205-1211
pubmed: 27832052
Lancet. 2011 Jul 2;378(9785):49-55
pubmed: 21722952
Cochrane Database Syst Rev. 2016 Apr 10;4:CD006611
pubmed: 27060875
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
Tob Control. 2004 Mar;13(1):85-6
pubmed: 14985603
Nicotine Tob Res. 2009 Jan;11(1):12-24
pubmed: 19246437
Addiction. 2016 Jul;111(7):1257-66
pubmed: 26748541
Tob Control. 2007 Dec;16 Suppl 1:i53-9
pubmed: 18048633
Tob Control. 2013 Nov;22(6):e11
pubmed: 23010696
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
Eur J Health Econ. 2013 Oct;14(5):789-97
pubmed: 22961230
Addiction. 2008 Sep;103(9):1553-61
pubmed: 18783507
Nicotine Tob Res. 2016 May;18(5):1046-53
pubmed: 26521269
Nicotine Tob Res. 2017 Nov 7;19(12):1473-1481
pubmed: 29121347
J Med Internet Res. 2017 Oct 03;19(10):e333
pubmed: 28974483
J Psychoactive Drugs. 2015 Apr-Jun;47(2):158-76
pubmed: 25950596
Cochrane Database Syst Rev. 2013 Aug 12;(8):CD002850
pubmed: 23934971
Prev Med. 2016 Aug;89:90-97
pubmed: 27154349
Am J Prev Med. 2014 Sep;47(3):242-50
pubmed: 24913220
Thorax. 2016 May;71(5):446-53
pubmed: 26931362
Nicotine Tob Res. 2017 Aug 1;19(8):901-907
pubmed: 27838659
Addiction. 2017 Apr;112(4):673-682
pubmed: 27943511
MMWR Morb Mortal Wkly Rep. 2017 Jan 06;65(52):1457-1464
pubmed: 28056007
Tob Control. 2017 Nov;26(6):683-689
pubmed: 27852892
Am J Prev Med. 2018 Jun;54(6):765-775
pubmed: 29674184
Lancet. 2016 Jan 30;387(10017):412-3
pubmed: 26803442
Tob Control. 2007 Dec;16 Suppl 1:i9-15
pubmed: 18048639
Prev Chronic Dis. 2010 Mar;7(2):A36
pubmed: 20158964
Nicotine Tob Res. 2003 Feb;5(1):13-25
pubmed: 12745503
Addiction. 2015 Sep;110(9):1388-403
pubmed: 26031929